MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia

Pharmacological Reports

Volumn 58, Issue 5, 2006, Pages 720-728

  Jamroziak, Krzysztof ^a   Balcerczak, Ewa ^a   Smolewski, Piotr ^a   Robey, Robert W ^b   Cebula, Barbara ^a   Panczyk, Mariusz ^a   Kowalczyk, Monika ^a   Szmigielska Kapłon, Anna ^a   Mirowski, Marek ^a   Bates, Susan E ^b   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABCB1; B CLL; Genetic susceptibility; MDR1; Multidrug resistance; Polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER CELL CULTURE; CANCER RISK; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33750985381     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ambdukar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 1999, 39, 361-398.
2. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 2001, 11, 217-221.
3. Bain LJ, LeBlanc: Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol, 1996, 141, 288-298.
4. Bain LJ, McLachlan JB, LeBlanc GA: Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect, 1997, 105, 812-818.
5. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, Colomer D et al.: For the GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears), Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol, 2002, 119, 976-984.
6. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L et al.: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet, 2003, 73, 1282-1292.
7. Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, Franco RF: Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+hematopoietic stem cells. Haematologica, 2002, 87, 564-568.
8. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med, 1989, 110, 236-238.
9. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera, A, Parisi G, Giustolisi GM et al.: Multidrug resistance mechanisms in chronic lymphocytic leukemia. Br J Haematol, 2002, 116, 774-780.
10. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the Pglycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 2003, 13, 259-263.
11. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet, 2002, 359, 30-36.
12. Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA, Mazza JJ et al.: Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma, 1999, 34, 171-178.
13. Hamblin TJ: Achieving optimal outcomes in chronic lymphocytic leukemia. Drugs, 2001, 61, 593-611.
14. Hatzissabas I, Krueger GR, Medina JR, Bedoya VA, Papadakis T: Environmental pollution and malignant lymphomas: a tentative contribution to geographic pathology. Anticancer Res, 1993, 13, 411-417.
15. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 2001, 11, 293-298.
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I et al.: Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3473-3478.
17. Houlston RS, Catovsky D, Yuille MR: Genetic susceptibility to chronic lymphocytic leukemia. Leukemia, 2002, 16, 1008-1014.
18. Illmer T, Shuler US, Thiede C, Schwarz UI, Kim RB, Gothard S, Freund D et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 2002, 62, 4955-4962.
19. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Hematol, 2004, 72, 314-321.
20. Jamroziak K, Balcerczak E, Mlynarski W, Mirowski M, Robak T: Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol, 2002, 54, 495-500.
21. Jamroziak K, Smolewski P, Cebula B, Szmigielska-Kaplon A, Darzynkiewicz Z, Robak T: Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia. Neoplasma, 2004, 51, 181-187.
22. Kurzawski M, Pawlik A, Gornik W, Drozdzik M: Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep, 2006, 58, 35-40.
23. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE: P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer, 1991, 49, 696-703.
24. Lanning CL, Fine RL, Sachs CW, Rao US, Corcoran JJ, Abou-Donia MB: Chlorpyrifos oxon interacts with mammalian multidrug resistance protein, P-glycoprotein. J Toxicol Environ Health, 1996, 47, 395-407.
25. Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Shen H, Zhao Y et al.: MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet, 2004, 41, e60.
26. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ et al.: French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 2001, 98, 2319-2325.
27. Lynch HT, Weisenburger DD, Quinn-Laquer B, Watson P, Lynch JF, Sanger WG: Hereditary chronic lymphocytic leukemia: an extended family study and literature review. Am J Med Genet, 2002, 115, 113-117.
28. Machulla HK, Muller LP, Schaaf A, Kujat G, Schonermarck U, Langner J: Association of chronic lymphocytic leukemia with specific alleles of the HLA-DR4:DR53:DQ8 haplotype in German patients. Int J Cancer, 2001, 92, 203-207.
29. Marwick C: Link between Agent Orange and chronic lymphocytic leukemia. BMJ, 2003, 326, 242.
30. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol, 2003, 65,1843-1852.
31. Nanni O, Amadori D, Lugaresi C, Falcini F, Scarpi E, Saragoni A, Buiatti E: Chronic lymphocytic leukemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding-workers: a population case-control study based on priori exposure matrices. Occup Environ Med, 1996, 53, 652-657.
32. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I: MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol, 2003, 17, 463-469.
33. Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ: Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 2002, 100, 2289-2290.
34. Robak T, Blonski JZ, Kasznicki M, Gora-Tybor I, Dwilewicz-Trojaczek J, Boguradzki P, Konopka L et al.: Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia, 2001, 15, 1510-1516.
35. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest, 1995, 96, 1698-1705.
36. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 2003, 124, 26-33.
37. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P et al.: Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol, 2002, 13, 1847-1854.
38. Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB: Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukemia and correlation with in vitro drug resistance. Leuk Res, 1993, 17, 941-947.
39. Svoboda-Beusan I, Kusec R, Bendelja K, Tudoric-Ghemo I, Jaksic B, Pejsa V, Rabatic S et al.: The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica, 2000, 85, 1261-1267.
40. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovesk S et al.: Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer, 2003, 97, 1711-1720.
41. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics, 2005,15, 693-704.
42. Waterhouse D, Carman WJ, Schottenfeld D, Gridley G, McLean S: Cancer incidence in the rural community of Tecumseh, Michigan: a pattern of increased lymphopoietic neoplasms. Cancer, 1996, 77, 763-770.
43. Webb M, Brun M, McNiven M, Le Couteur D, Craft P: MDR1 and MRP expression in chronic B-cell lymphoprolifartive disorders. Br J Haematol, 1998, 102, 710-717.
44. Yuille M, Condie A, Hudson C, Kote-Jarai Z, Stone E, Eeles R, Matutes E et al.: Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood, 2002, 99, 4216-4218.